NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 68 resultados LastUpdate Última actualización 11/07/2020 [14:20:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   por página


PRODUCTS AND COMPOSITIONS

NºPublicación: US2020208158A1 02/07/2020

Solicitante:

SILENCE THERAPEUTICS GMBH [DE]

BR_112019019921_A2

Resumen de: US2020208158A1

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as β-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.

traducir

AUXILIARY DIAGNOSTIC METHOD FOR INTRAOCULAR MALIGNANT LYMPHOMA

NºPublicación: WO2020138435A1 02/07/2020

Solicitante:

UNIV TOKYO [JP]

Resumen de: WO2020138435A1

The purpose of the present invention is to provide an auxiliary diagnostic method for intraocular malignant lymphomas that includes detecting an intraocular malignant lymphoma-specific gene mutation. Specifically, the present invention is an auxiliary diagnostic method for intraocular malignant lymphomas that includes, from a subject-derived sample, detecting one or more from among the gene mutations of (A) to (I) below: (A) c.586T>A mutation of CD79B; (B) c.586T>C mutation of CD79B; (C) c.587A>C mutation of CD79B; (D) c.587A>G mutation of CD79B; (E) c.133G>A mutation of BTG2; (F) c.142G>A mutation of BTG2; (G) c.794T>C mutation of MYD88; (H) c.728G>A mutation of MYD88; and (I) c.550C>T mutation of PIM1.

traducir

CD7 CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92MI CELL AND USE THEREOF

NºPublicación: WO2020135870A1 02/07/2020

Solicitante:

PERSONGEN BIOTHERAPEUTICS SUZHOU CO LTD [CN]

CN_109652379_A

Resumen de: WO2020135870A1

The present invention provides a CD7 chimeric antigen receptor-modified NK-92MI cell and use thereof. In particular, the present invention provides an engineered NK cell expressing a chimeric antigen receptor (CAR), said CAR having an antigen-binding domain containing a nanobody VHH sequence targeting CD73. Said NK cell of the present invention can effectively kill tumor cells, especially T cell tumors, and has a good therapeutic effect on T cell leukemia (such as T-ALL).

traducir

METHODS FOR IDENTIFYING MYELOMA TUMOR-INITIATING CELLS AND TARGETED THERAPY

NºPublicación: US2020209247A1 02/07/2020

Solicitante:

UNIV IOWA RES FOUND [US]

WO_2019055930_A1

Resumen de: US2020209247A1

In certain embodiments, the present invention provides a method of treating cancer in a patient comprising administering an effective amount of a therapeutic agent to the patient, wherein the cancer was determined to contain cells comprising cell marker CD24+. In certain embodiments, the cancer cells also comprise cell markers CD38+ and/or CD45−.

traducir

COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASES

NºPublicación: US2020206190A1 02/07/2020

Solicitante:

CELGENE INT II SARL [CH]
DANA FARBER CANCER INST INC [US]

JP_2015028089_A

Resumen de: US2020206190A1

Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.

traducir

USE OF FLT3 CAR-T CELLS AND FLT3 INHIBITORS TO TREAT ACUTE MYELOID LEUKEMIA

NºPublicación: US2020206266A1 02/07/2020

Solicitante:

UNIV WUERZBURG J MAXIMILIANS [DE]

CA_3071303_A1

Resumen de: US2020206266A1

The invention generally relates to the treatment of cancer with FLT3 targeting agents and kinase inhibitors. In particular, the invention relates to adoptive immunotherapy of Acute Myeloid Leukemia (AML) with chimeric antigen receptor (CAR)-modified T cells specific for FMS-like tyrosine kinase (FLT3) in combination with FLT3 inhibitors.

traducir

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS

NºPublicación: US2020207831A1 02/07/2020

Solicitante:

IMMATICS BIOTECHNOLOGIES GMBH [DE]

US_2020199193_A1

Resumen de: US2020207831A1

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

traducir

METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA

NºPublicación: US2020207859A1 02/07/2020

Solicitante:

SUTRO BIOPHARMA INC [US]

WO_2019023316_PA

Resumen de: US2020207859A1

Provided herein are antibody conjugates with binding specificity for CD74 and compositions comprising the antibody conjugates, including pharmaceutical compositions, methods of producing the conjugates, and methods of using the conjugates and compositions for therapy involving treatment, amelioration, and/or diagnosis of a T-cell lymphoma.

traducir

CD19CART CELLS ELIMINATE MYELOMA CELLS THAT EXPRESS VERY LOW LEVELS OF CD19

NºPublicación: US2020209240A1 02/07/2020

Solicitante:

UNIV WUERZBURG J MAXIMILIANS [DE]

WO_2019097082_A1

Resumen de: US2020209240A1

The invention generally relates to immunotherapy with chimeric antigen receptor (CAR}- engineered T-cells. In particular, the invention relates immunotherapy with chimeric antigen receptor (CAR)-engineered T-cells to target sub-populations of cancer cells that are characterized by low expression of a cancer cell surface antigen, more particular the invention relates to immunotherapy with chimeric antigen receptor (CAR)-engineered T-cells targeting CD19 (CD19CART) in multiple myeloma, a clonal proliferation of plasma cells.

traducir

COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE

NºPublicación: US2020206333A1 02/07/2020

Solicitante:

HARVARD COLLEGE [US]
MASSACHUSETTS GEN HOSPITAL [US]

WO_2018227205_PA

Resumen de: US2020206333A1

Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor cells. It is a devastating disease with a poor prognosis and an average 5-year survival rate of about 30%. Disclosed herein are composition and methods for treating leukemia with a biomaterial comprising a polymer scaffold, a dendritic cell activating factor, a dendritic cell recruitment factor, and at least one leukemia antigen. The biomaterial-based vaccine disclosed herein promotes a potent, durable and transferable immune response against acute myeloid leukemia to prevent cell engraftment and synergizes with chemotherapy to prevent relapse.

traducir

CELL CULTURE METHODS AND MEDIA COMPRISING N-ACETYLCYSTEINE

NºPublicación: US2020208100A1 02/07/2020

Solicitante:

MEDIMMUNE LLC [US]

AU_2019204934_A1

Resumen de: US2020208100A1

This application provides improved cell culture media and cell culture methods comprising N-acetylcysteine. These improved cell culture media and cell culture methods increase cell viability, cellular growth rate and/or reduce cell doubling time of cholesterol auxotrophic cells, myeloma cells, and hybridoma cells.

traducir

COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF

NºPublicación: US2020206228A1 02/07/2020

Solicitante:

MORPHOSYS AG [DE]

ES_2754431_T3

Resumen de: US2020206228A1

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

traducir

METHOD AND KIT FOR PREDICTING THERAPEUTIC EFFECTIVENESS OF CHEMOTHERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS

NºPublicación: EP3674416A1 01/07/2020

Solicitante:

UNIV KYUSHU NAT UNIV CORP [JP]

WO_2019065901_PA

Resumen de: EP3674416A1

A method is provided for predicting the therapeutic effectiveness of chemotherapy for a diffuse large B-cell lymphoma patient, including: at least one step selected from the group consisting of a step of measuring expression of a marker of a T cell in a sample obtained from the patient, a step of measuring expression of a marker of a macrophage or a dendritic cell in a sample obtained from the patient, and a step of measuring expression of a marker of a stromal cell in a sample obtained from the patient; and a step of predicting prognosis of the treatment, based on the expression of the marker.

traducir

Composition for prevention or treatment of leukemia comprising mother's milk-derived ingredient

NºPublicación: KR20200075404A 26/06/2020

Solicitante:

주다빈치큐

Resumen de: KR20200075404A

본 발명은 모유 유래 성분을 유효성분으로 포함하는 백혈병 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 모유 유래 성분은 만성골수성 백혈병 세포주에서 거핵구 분화 및 세포사멸을 유도하는 효과를 가지고 있는바, 백혈병의 개선, 예방 또는 치료 분야에서 다양하게 활용될 수 있다.

traducir

USE OF CD2/5/7 KNOCK-OUT ANTI-CD2/5/7 CHIMERIC ANTIGEN RECEPTOR T CELLS AGAINST T CELL LYMPHOMAS AND LEUKEMIAS

NºPublicación: WO2020132327A1 25/06/2020

Solicitante:

UNIV PENNSYLVANIA [US]

Resumen de: WO2020132327A1

The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.

traducir

ASPARAGINASE-INDUCED GLUTAMINE DEPLETION COMBINED WITH BCL-2 INHIBITION FOR TREATMENT OF HEMATOLOGIC AND SOLID CANCERS

NºPublicación: WO2020132184A1 25/06/2020

Solicitante:

UNIV MARYLAND [US]
EMADI ASHKAN [US]
LAPIDUS RENA G [US]

Resumen de: WO2020132184A1

Methods of treating cancer and prolonging survival of a subject having cancer, such as acute myeloid leukemia, via administration of therapeutically effective amounts of agents that depletes plasma glutamine and agents that inhibit BCL-2 activity are detailed herein. Suitable agents that depletes plasma glutamine include asparaginase. Suitable agents that inhibit BCL-2 activity include Venetoclax.

traducir

T-CELL MODULATORY MULTIMERIC POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF

NºPublicación: WO2020132366A2 25/06/2020

Solicitante:

CUE BIOPHARMA INC [US]

Resumen de: WO2020132366A2

The present disclosure provides T-cell modulatory multimeric polypeptide epitope conjugates comprising an immunomodulatory polypeptide ("MOD") that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide ("Co-MOD") and a conjugated Wilms tumor-1 (WT-1) epitope presenting peptide. The T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for IL-2R, to the T-cells in a WT-1 epitope selective/specific manner, and accordingly, for treating individuals, particularly those with acute myeloid leukemia, myeloma, ovarian cancer, pancreatic cancer, non-small cell lung cancer, colorectal cancer, breast cancer, Wilms tumor, mesothelioma, soft tissue sarcoma, neuroblastoma, or nephroblastoma.

traducir

ANTICANCER COMPOSITION CONTAINING CANCER CELL LINE-DERIVED AMF AS ACTIVE INGREDIENT

NºPublicación: WO2020130519A1 25/06/2020

Solicitante:

PARK HEE SUNG [KR]

Resumen de: WO2020130519A1

The present invention relates to an anticancer composition containing a cancer cell line-derived AMF as an active ingredient. More specifically, cancer cell line-derived AMF of the present invention has an excellent effect of inhibiting the proliferation of one or more cancers selected from the group consisting of leukemia, colorectal cancer, laryngeal cancer, breast cancer, prostate cancer, brain cancer and bladder cancer, and an effect of causing apoptosis thereof, and thus the composition, of the present invention, containing cancer cell line-derived AMF as an active ingredient can be used as an anticancer therapeutic agent.

traducir

NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES

NºPublicación: US2020199172A1 25/06/2020

Solicitante:

PACIFIC ARROW LTD [CN]

Resumen de: US2020199172A1

This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases. The compounds are attached with angeloyl, acetyl, tigloyl, senecioyl, Crotonoyl, 3,3-Dimethylacryloyl, Cinnamoyl, Pentenoyl, Hexanoyl, benzoyl, Ethylbutyryl, benzoyl, dibenzoyl, alkanoyl, alkenoyl, benzoyl alkyl substituted alkanoyl, ethanoyl, propanoyl, propenoyl, butanoyl, butenoyl, pentanoyl, hexenoyl, heptanoyl, heptenoyl, octanoyl, octenoyl, nonanoyl, nonenoyl, decanoyl, decenoyl, propionyl, 2-propenoyl, 2-butenoyl, Isobutyryl, 2-methylpropanoyl, 2-ethylbutyryl, ethylbutanoyl, 2-ethylbutanoyl, butyryl, (E)-2,3-Dimethylacryloyl, (E)-2-Methylcrotonoyl, 3-cis-Methyl-methacryloyl, 3-Methyl-2-butenoyl, 3-Methylcrotonoyl, 4-Pentenoyl, (2E)-2-pentenoyl, Caproyl, 5-Hexenoyl, Capryloyl, Lauroyl, Dodecanoyl, Myristoyl, Tetradecanoyl, Oleoyl, O—C(2-18) Acyl.

traducir

COMPOSITION FOR USE AS A SUPPORT THERAPY FOR TREATMENT OF TUMOURS, AIDS AND LEUKAEMIA

NºPublicación: US2020197453A1 25/06/2020

Solicitante:

BENASSAI CHIARA [IT]
MOGNA ELENA [IT]
MOGNA VERA [IT]

Resumen de: US2020197453A1

Described in the instant application are methods and compositions for support therapy in antitumor chemotherapeutic treatments, in acquired immunodeficiency syndrome treatments and in leukemia treatments. Said methods and compositions comprise a bacterial strain belonging to the species Lactobacillus pentosus and having an antiviral and an antibacterial activity, and a highly bioavailable zinc internalized in a tyndalized bacterial cell mixed with at least one rubber, and in particular an alginate and/or a gel, and in particular a gel.

traducir

CD22-SPECIFIC T CELL RECEPTORS AND ADOPTIVE T CELL THERAPY FOR TREATMENT OF B CELL MALIGNANCIES

NºPublicación: WO2020127357A1 25/06/2020

Solicitante:

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ GEMEINSCHAFT [DE]
UNIV BERLIN CHARITE [DE]

EP_3670530_A1

Resumen de: WO2020127357A1

The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer, in particular, of B cell lymphoma or B cell leukemia. The invention provides a nucleic acid encoding TCR alpha or beta chain constructs of TCR constructs capable of specifically binding to a peptide of SEQ ID NO: 1, derived from the lineage specific antigen CD22, in the context of HLA-A2 and to subsequently lyse CD22-positive cells. The invention further provides a corresponding protein and host cell, e.g., a CD8+ T cell, pharmaceutical compositions comprising the same, and therapeutic use for treatment of B cell lymphoma or B cell leukemia, such as diffuse large B-cell lymphoma (DLBCL).

traducir

PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB

NºPublicación: WO2020127912A1 25/06/2020

Solicitante:

SYNTHON BV [NL]

EP_3669867_A1

Resumen de: WO2020127912A1

The present invention relates to a tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, characterized in that: • Ibrutinib is form C, having characteristic peaks in the X-ray powder diffraction pattern at the following 2 theta (±0.2) angles: 6.9º, 18.2º, 19.2º, 19.6º and 23.0º, measured using a Cu Kα radiation; and • Ibrutinib form C is present in an amount from 60 to 80% w/w relative to the total weight of the tablet; and • The composition is free of surfactant; and • The composition exhibits a dissolution rate of at least 65% in 20 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 (+1% Tween 20) at 37ºC, 75 rpm and/or in 900 ml phosphate buffer pH 6.8 (+3% Tween 20) at 37ºC, 75 rpm in a USP apparatus II. The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenstrӧm's macroglobulinaemia (WM).

traducir

CD70 AND VENETOCLAX, A BCL-2 INHIBITOR, COMBINATION THERAPY FOR TREATING ACUTE MYELOID LEUKEMIA

NºPublicación: WO2020127503A1 25/06/2020

Solicitante:

ARGENX BVBA [BE]
UNIV OF BERN [CH]

Resumen de: WO2020127503A1

The invention relates to combination therapies, particularly combination therapies for the treatment of myeloid malignancy. The combination therapies are particularly useful in methods for the treatment of acute myeloid leukemia (AML). The combination therapies include an antibody or antigen binding fragment thereof that binds to CD70 and a BCL-2 inhibitor, preferably venetoclax or a pharmaceutically acceptable salt thereof.

traducir

7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER

NºPublicación: WO2020131674A1 25/06/2020

Solicitante:

ARRAY BIOPHARMA INC [US]

Resumen de: WO2020131674A1

Provided herein are 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X 2 is N and Ring A, Ring B, Ring C, X 1, X 3, R 1, L, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, such as e.g. cancer, e.g. bladder cancer, brain cancer, breast cancer, cholangiocarcinoma, head and neck cancer, lung cancer, multiple myeloma, rhabdomyosarcoma, urethral cancer and uterine cancer. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 276 to 308; examples 1 to 30; examples A to E; tables CA to EE). An exemplary compound is e.g. 1-(3-(4-(4-(7-((3,5-dimethoxy phenyl) amino)quinoxalin-2-yl)-1H-pyrazol-l-yl)piperidine-1-carbonyl) azetidin-1-yl)prop-2-en-1-one (e.g. example 1).

traducir

PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB

Nº publicación: US2020197312A1 25/06/2020

Solicitante:

SYNTHON BV [NL]

Resumen de: US2020197312A1

The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinaemia (WM).

traducir

Página1 de 3 nextPage por página

punteroimgVolver